NanoString Technologies, Inc. (NSTGQ) Research

NanoString Technologies, Inc. specializes in creating, producing, and distributing advanced technological solutions for generating scientific and clinical insights within the genomics and proteomics sectors. Their operations span across global markets, including the Americas, Europe, the Middle East, and the Asia Pacific region. The company's core offering is the nCounter Analysis System, an automated and versatile digital platform for detecting and quantifying biological targets. This system comprises nCounter Pro and FLEX variants, which include the Prep Station, an automated liquid handler meticulously designed to process and ready samples for data acquisition. Subsequently, the nCounter Digital Analyzer captures data from these prepared samples by imaging immobilized fluorescent reporters within specialized cartridges, then converting this visual information into actionable output files. NanoString also provides the nCounter SPRINT Profiler, an instrument that integrates liquid handling with digital analysis through a microfluidic cartridge. For data interpretation, researchers rely on the nSolver Analysis Software, a robust program enabling them to verify, standardize, and thoroughly analyze their experimental results. The product portfolio further extends to specialized custom CodeSets and pre-designed panels tailored for applications in oncology, immunology, infectious diseases, and neuroscience. Additionally, a comprehensive range of consumables, such as Master Kits, cartridges, ancillary reagents, tips, and reagent plates, are available to facilitate instrument setup and sample processing. The company also offers Prosigna in vitro diagnostic kits. In terms of future innovation, NanoString is actively developing the GeoMx DSP system, intended to advance the emerging field of spatial biology. The company has forged significant partnerships, including one with Lam Research Corporation for the development of a next-generation sequencing (NGS) platform and associated assays. Another collaboration is with the Parker Institute for Cancer Immunotherapy, focused on creating CAR-T therapies aimed at improving patient prognosis across various cancer types. Further strategic alliances involve Stanford Medicine, Acrobat Genomics, and Illumina Accelerator, all geared towards identifying novel drug targets for gene editing applications. Founded in 2003, NanoString Technologies is headquartered in Seattle, Washington. However, on February 4, 2024, the company and its affiliates initiated voluntary Chapter 11 bankruptcy proceedings for reorganization in the U.S. Bankruptcy Court for the District of Delaware.

Open NanoString Technologies, Inc. (NSTGQ) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.